Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Saltos
Dr. Andreas Saltos is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Maryland School of Medicine and has been in practice 8 years. He is one of 183 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 20 publications and over 500 citings.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2015 - 2018
University of MarylandResidency, Internal Medicine, 2012 - 2015
University of Maryland School of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2015 - 2027
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Start of enrollment: 2016 Nov 23
- Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Start of enrollment: 2018 Nov 29
- Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung Cancer.Brian D Gonzalez, Xiaoyin Li, Lisa M Gudenkauf, Jerrin J Pullukkara, Laura B Oswald
JCO Clinical Cancer Informatics. 2025-09-01 - Reply to: Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results.Xiuning Le, Mike Hernandez, Simon Heeke, Andreas Saltos, John V Heymach
Journal of Clinical Oncology. 2025-05-01 - 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01
Press Mentions
Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 plus Docetaxel in Advanced Non-Small Cell Lung CancerAugust 25th, 2025- Moffitt Initiates Groundbreaking Clinical Trial with Oncolytic Virus for Non-Small Cell Lung CancerMay 1st, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
